No profile data available.
CNS Pharmaceuticals, Inc. (CNSP) is a healthcare company in the additional cancer treatment drugs industry, based in Houston, United States, with about 8 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$15.85 million. Its market capitalization was $7.82 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States.
CNS Pharmaceuticals reported $0 in revenue for fiscal year 2025.
$7.82 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Oncotelic Therapeutics, Inc. (OTLC), Moleculin Biotech, Inc. (MBRX), Bolt Biotherapeutics, Inc. (BOLT), Aprea Therapeutics, Inc. (APRE).